Rush Cancer Institute is a clinical research site located in Chicago, Illinois, United States 60612.
Crixeo Health Trust Score: 79/100 (FAIR). This profile has not yet been claimed by the site owner.
Rush Cancer Institute has participated in 13 clinical trials.
Therapeutic areas: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes.
Sponsors: Rush University Medical Center, Genzyme, a Sanofi Company, Chiron Corporation.
Trust Score: 79/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Rush Cancer Institute has a Crixeo Trust Score of 79/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Rush Cancer Institute has 13 clinical trials on record. Their work covers Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes.
Yes — Rush Cancer Institute holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.